Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
322
resultados
Última actualización
25/08/2026 [07:57:00]
Resultados 50 a 75 de 322
Resumen de: CN122525131A
本发明属于检测技术领域，本发明具体公开了一种磷酸化Tau217蛋白测定试剂盒及应用，本申请所述的磷酸化Tau217蛋白测定试剂盒包括特定的抗试剂A、抗试剂B和磁微粒试剂，所述的生物素标记的p‑Tau 217抗体与碱性磷酸酶标记的p‑Tau 217抗体反应生成，抗体‑抗原‑抗体复合物并通过生物素与链霉亲和素的特异性结合反应结合到磁性微粒上，能够有效的降低检测限，实现了磷酸化Tau217蛋白的高灵敏度检测，空白限不高于0.20pg/mL，且在0.50pg/mL~50.00pg/mL范围内线性相关性好（r≥0.9900），可实现磷酸化Tau217蛋白的准确定量。
Resumen de: CN122525140A
0001 本发明涉及生物标志物组合在制备用于APOE ε3/ε3基因型个体阿尔茨海默病的检测试剂盒中的应用，所述的生物标志物选自ANGPTL1，PON2，PTN，SCGB3A1，PBLD，MORC3，EIF5A，FAM3D，PIKFYVE，CKB，HGF，TREH，GSTA3，EIF2AK3，CTSD，FOLH1中的至少一种，实现了在该人群中对阿尔茨海默病高精度、高特异性的体外诊断。
Resumen de: WO2026163093A1
Two proteins, Elastase 3B and igKappa chain, are identified as biomarkers for the diagnosis and prognosis of Alzheimer's disease (Alzheimer Disease, AD). These proteins can be detected in fecal samples from subjects affected by this pathology and exhibit a statistically significant variation in samples from AD subjects compared with the levels detected in a healthy reference sample, thereby making it possible to provide both diagnosis and prognosis of AD in a simple and non-invasive manner, in particular, Elastase 3B and igKappa chain emerge as complementary biomarkers with opposite and progressive modulation. Specifically, Elastase 3B decreases in all phases of the pathology, whereas igKappa chain shows a progressive increase that reflects the progression of AD. The combined use of these two proteins as complementary biomarkers is therefore applicable for the early diagnosis and prognosis of AD. To achieve this objective, a strategy based on the use of a preclinical model was adopted, namely the triple-transgenic murine model (3xTg-AD), which mimics the AD pathology observed in humans and reproduces its characteristics and different stages. Based on the premise that the results obtained may also be predictive for humans, the use > of the murine model offers an important advantage, namely the possibility of collecting samples to be analyzed at precise time points, thereby allowing the study of the pathology in its different stages, from the asymptomatic phase to the early sym
Resumen de: WO2026165150A2
Disclosed herein are methods pertaining to analyzing a biological sample from a subject for a neurodegenerative disease. In one aspect, the disclosure relates to a method for analyzing a biological sample from a subject for a neurodegenerative disease. This method involves determining a ratio of pTau217 to BD-Tau present in a biological sample obtained from a subject and diagnosing the subject as (i) having Alzheimer's disease when the ratio of pTau217 to BD-Tau in the sample is a at least a first predetermined value; (ii) a healthy subject (no neurodegenerative disease) when the ratio of pTau217 to BD-Tau in the sample is below a second predetermined value; and/or (iii) having a disease other than Alzheimer's disease associated with high levels of pTau217 when the ratio of pTau217 to BD-Tau in the sample is between the second predetermined value and the first predetermined value.
Resumen de: US20260226658A1
0000 Aspects of the present invention disclose compounds that modulate the aggregation of amyloidogenic proteins or peptides. In some aspects, disclosed compounds modulate the aggregation of disease-associated proteins and natural β-amyloid peptides. In a preferred embodiment, the compounds can inhibit natural amyloid aggregation. Pharmaceutical compositions comprising the compounds of the embodiments, and diagnostic and treatment methods for diseases (e.g., amyloidogenic diseases) using the compounds, are also disclosed. In addition, there is provided an integrated bacterial platform for the discovery of rescuers of disease-associated protein misfolding.
Resumen de: US20260227416A1
0000 The invention relates to diagnosis, prevention, and treatment of diseases and conditions associated with the functions of prion-like or Tetz-proteins.
Resumen de: WO2021039644A1
The present invention addresses the problem of providing a method for quantifying Hex4, lyso-GM1, Fuc-GlcNAc-Asn, or lyso-sulfataide in a brain. The present invention relates to a method for quantifying Hex4, lyso-GM1, Fuc-GlcNAc-Asn, or lyso-sulfataide included in a cerebrospinal fluid, the method comprising: a step for adding an internal standard substance to a solution containing the cerebrospinal fluid; a step for subjecting the solution, which contains the cerebrospinal fluid and to which the internal standard substance is added, to liquid chromatography to obtain an effluent; and a step for providing the effluent for mass spectrometry.
Resumen de: US20260227396A1
0000 A method for identifying a multi-parameter phenotype of microbiota. The method includes (i) providing a sample including microbiota, (ii) labeling the microbiota with multiple labels, each of which binds a phenotypic parameter of the microbiota, (iii) detecting an intensity of the labelled phenotypic parameters of single cells of the microbiota by flow cytometry, and (iv) segmenting the single cells into bins based on the intensities of detected phenotypic parameters, wherein the distribution of single cells in bins represents a multi-parameter phenotype of said microbiota. Also described is a system for identifying a multi-parameter phenotype of intestinal microbiota, a kit for identifying a multi-parameter phenotype of intestinal microbiota and methods for diagnosing a medical condition associated with microbiota, for example an inflammatory condition, such as an inflammatory bowel disease, in a subject.
Resumen de: US20260226143A1
0000 Antibodies that bind human beta-amyloid peptide, methods of detecting, measuring and treating amyloidogenic disorders with said antibodies, pharmaceutical compositions comprising the antibodies and methods of manufacture are provided.
Resumen de: US20260224661A1
Methods are provided for enhancing synaptogenesis. It is shown herein that the receptor for the circulating factor SPARCL1 (secreted protein acidic and rich in cysteine-like protein) are teneurin proteins (Tenm1-4). The binding site for SPARCL1 is localized to domain 3, which specifically binds to the C terminal domain of SPARCL1 (SPARCL1-C). Contacting neuronal cells expressing a teneurin protein with SPARC is sufficient to increase synapse formation on the neuronal cells.
Resumen de: US20260226173A1
The present technology relates generally to compositions that specifically recognize and bind to a WT-1 peptide complexed with a major histocompatibility antigen (e.g., HL A-A*02). The compositions of the present technology are useful in methods for treating WT-1-associated diseases (e.g., cancers) in a subject in need thereof.
Resumen de: US20260224206A1
An excrement analysis apparatus includes an inputter, a memory, a first analyzer, and a second analyzer. The inputter inputs imaging data captured by an image capture apparatus installed in such a way as to include, in a capturing range, an excretion range of excrement in a toilet bowl of a toilet. The memory temporarily holds the imaging data input by the inputter. The first analyzer analyzes first analysis target data being the imaging data input by the inputter, and outputs notification information to an observer who observes a user of the toilet. The second analyzer analyzes second analysis target data being the imaging data that is input by the inputter and temporarily held by the memory, and outputs detailed information indicating a content of excretion.
Resumen de: US20260227408A1
0000 The disclosure provides, in various embodiments, compositions, such as polypeptides, polynucleotides, gene editing system, small molecules, vectors or host cells, that comprises and/or modulate expression or activity of immune regulation-associated proteins. The disclosure also provides, in various embodiments, methods of treating aging, senescence, fibrosis, autoimmunity, cancer, an infection, and/or an immunological disease using an agent that comprises and/or modulates expression or activity of an immune regulation-associated protein and methods of identifying said agent.
Resumen de: US20260229316A1
Embodiments herein describe systems and methods to generate a risk score for an individual to develop postoperative neurocognitive disorder (POND). Various embodiments obtain multi-omics data from an individual, such as genomics, transcriptomics, and proteomics. In certain embodiments, a machine learning algorithm is used to generate the risk score based on the multi-omics data. In further embodiments, clinical data is further used in the determination of the risk score.
Resumen de: US20260224626A1
0000 The disclosure relates to methods for predicting a likelihood of a relapse to a cancer in a patient following treatment of the patient with an immunotherapy product, and methods for improving efficacy of an immunotherapy product for a patient with a likelihood of a relapse to a cancer following treatment with an immunotherapy product.
Resumen de: WO2026161967A1
A pharmaceutical composition co-formulating insulin and C-peptide for simultaneous delivery to restore physiological coordination is described. The invention is based on the discovery, validated by advanced artificial intelligence (AI) modeling, that C-peptide acts on at least three distinct receptors (the Insulin Receptor, GPR146, and RXFP1) to potentiate insulin signaling, terminate pro-metabolic signals that lead to hypercortisolemia and dyslipidemia, and activate anti-fibrotic pathways. This approach is supported by a model of an integrated hormonal network where the relaxin, C-peptide, and cortisol systems are interwoven through central neuroendocrine modulation, direct molecular crosstalk, and metabolic convergence. These coordinated mechanisms provide comprehensive diabetes management beyond glucose control. The co-formulation is approximately 7-fold more mass-efficient than insulin monotherapy. Furthermore, the invention provides a dual-mechanism neuroprotective therapy for Alzheimer's disease by inhibiting amyloid-beta production in neurons and promoting its clearance by microglia via a novel neuro-immune pathway.
Resumen de: US20260226177A1
0000 The present disclosure provides humanized anti-GluN1 receptor antibodies and antigen-binding fragments or derivatives thereof, which are effective in inhibiting the deleterious effects of tissue-type plasminogen activator (t-PA) mediated by N-methyl-D-aspartate (NMDA) receptors, as well as pharmaceutical compositions and medical uses thereof, particularly for the treatment of neurological, neurovascular or neurodegenerative disorders, such as stroke, multiple sclerosis, Parkinson's disease, and others.
Resumen de: US20260226172A1
The invention provides programmed death-ligand 1 (PD-L1) antibodies and methods of using the same.
Resumen de: US20260227412A1
The present invention provides for the use of IFN-I activity as a predictive biomarker for the treatment of patients with toll-like receptor (TLR) inhibitors and related uses and methods.
Resumen de: EP4786984A1
The invention relates to a matrix configured for use in an extracorporeal blood treatment device, wherein the matrix comprises a solid substrate, to which an agent is immobilized, wherein said agent specifically binds mitochondrial DNA (mtDNA) in the blood or blood plasma of a subject. The invention also relates to methods for preparing the matrix according to the present invention, wherein the oligonucleotide and/or the polypeptide is immobilized on the solid substrate of the matrix by covalent coupling, preferably by crosslinking. The invention further relates to a blood treatment device configured to remove mtDNA from the blood or blood plasma of a person in need thereof in an extracorporeal blood circuit, wherein the device comprises a matrix according to the present invention. The invention further relates to an extracorporeal blood circuit comprising a blood treatment device according to the present invention, wherein the extracorporeal blood circuit comprises means for transporting blood or blood plasma from a patient's vascular system to the blood treatment device at a defined flow rate and means for returning the treated blood or blood plasma back to the patient.
Resumen de: EP4785940A1
0001 The present invention relates to pharmaceutical combinations, pharmaceutical compositions, kits comprising a compound of formula (I), a pharmaceutically acceptable salt thereof, a prodrug thereof, or a metabolite thereof, and a TNFα-inhibitor. The present invention also relates to said pharmaceutical combinations for use in the treatment of an inflammatory disease, disorder, or condition. The compound of formula (I) has the following formula:
Resumen de: EP4786977A1
A method for identifying biomarkers of a health condition, comprising: providing a first neuronal circuit with neuronal cells from a first individual organism on a multi-electrode array, applying stimuli to the circuit, obtaining electrophysiological recordings, deriving cell-level and/or circuit-level features from the recordings, associating derived features with presence or absence of the health condition, comparing associated data with reference data, and determining if reference features or derived features are biomarkers for the condition.
Resumen de: TW202542522A
Among the various aspects of the present disclosure is the provision of assay methods to identify diseases associated with orexin levels. The present teachings include methods to quantify an orexin concentration in a fluid sample, such as a cerebrospinal fluid sample, and identifying and treating diseases, including but not limited to narcolepsy and Alzheimer's disease, from the orexin concentration.
Resumen de: CN122506168A
本发明公开了一种基于金纳米颗粒的等离子增强荧光偶联适配体比率传感器的制备方法及其在淀粉样蛋白可视化检测中的应用。本发明制备金纳米颗粒，通过加入EDC/NHS将金纳米颗粒固定在氨基化的酶标板上；使两端分别修饰氨基和巯基的β‑淀粉样蛋白适配体形成Au‑S键接枝至金纳米颗粒修饰的酶标板；加入EDC/NHS将孟加拉玫瑰通过酰胺键接枝至金纳米颗粒上的适配体上得到以等离子体增强荧光偶联适配体作为响应荧光探针，以9‑蒽甲酸作为参比荧光制得等离子增强/比率荧光探针传感器。本发明制备的等离子增强/比率荧光探针传感器的稳定性好，实现便携式、超灵敏和特异性的β‑淀粉样蛋白可视化定量检测。
Nº publicación: CN122503499A 04/08/2026
Solicitante:
中日友好医院（中日友好临床医学研究所）
Resumen de: CN122503499A
本发明涉及生物医药技术领域，尤其是涉及基于LTF的PASC相关心血管系统症状风险评估应用。本发明提供了一种以LTF为核心分子标志物的风险评估体系，该体系能够在常规检测手段难以提供充分解释的情况下，为PASC相关心血管系统症状风险评估提供客观、可量化的分子层面参考依据。
BOPI
Sede Electrónica
